研究单位：[1]Xuanwu Hospital ,Capital Medical University,Beijing,Beijing,China,100053[2]Shengqi Medical Technology (Guangzhou) Co., Ltd.[3]Viyun (Xiamen) Biomedical Research Institute Co., Ltd
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.
